Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

ABSTRACT Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David S. Fedson, Steven M. Opal, Ole Martin Rordam
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	COVID-19 endothelial dysfunction generic drugs host response treatment Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/8db023d0a86544279a73edcb5f5de50a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8db023d0a86544279a73edcb5f5de50a
record_format	dspace
spelling	oai:doaj.org-article:8db023d0a86544279a73edcb5f5de50a2021-11-15T15:57:03ZHiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection10.1128/mBio.00398-202150-7511https://doaj.org/article/8db023d0a86544279a73edcb5f5de50a2020-04-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00398-20https://doaj.org/toc/2150-7511ABSTRACT Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.David S. FedsonSteven M. OpalOle Martin RordamAmerican Society for MicrobiologyarticleCOVID-19endothelial dysfunctiongeneric drugshost response treatmentMicrobiologyQR1-502ENmBio, Vol 11, Iss 2 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 endothelial dysfunction generic drugs host response treatment Microbiology QR1-502
spellingShingle	COVID-19 endothelial dysfunction generic drugs host response treatment Microbiology QR1-502 David S. Fedson Steven M. Opal Ole Martin Rordam Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
description	ABSTRACT Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
format	article
author	David S. Fedson Steven M. Opal Ole Martin Rordam
author_facet	David S. Fedson Steven M. Opal Ole Martin Rordam
author_sort	David S. Fedson
title	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
title_short	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
title_full	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
title_fullStr	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
title_full_unstemmed	Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
title_sort	hiding in plain sight: an approach to treating patients with severe covid-19 infection
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/8db023d0a86544279a73edcb5f5de50a
work_keys_str_mv	AT davidsfedson hidinginplainsightanapproachtotreatingpatientswithseverecovid19infection AT stevenmopal hidinginplainsightanapproachtotreatingpatientswithseverecovid19infection AT olemartinrordam hidinginplainsightanapproachtotreatingpatientswithseverecovid19infection
_version_	1718427039815434240

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

Ejemplares similares